Lars Møller Pedersen
Clinical Associate Professor
Department of Clinical Medicine
Køgevej 7 - 13, 4000 Roskilde
Member of:
Internal Medicine: Haematology
1 - 1 out of 1Page size: 10
- 2018
- Published
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy
Ahmad, S. M., Martinenaite, E., Holmström, M., Jørgensen, M. A., Met, Özcan, Nastasi, C., Klausen, U., dqp123, dqp123, Pedersen, Lars Møller, Munksgaard, Lars, Ødum, Niels, Woetmann, Anders , Svane, Inge Marie & Andersen, Mads Hald, 2018, In: OncoImmunology. 7, 2, 10 p., e1390641.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 170755381
Most downloads
-
20
downloads
An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
16
downloads
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
Research output: Contribution to journal › Journal article › Research › peer-review
Published